How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

Cancer

Stomach (Gastric) Cancer Clinical Trials in the UK

Find clinical trials for stomach cancer in the United Kingdom. Explore treatment pathways including immunotherapy, targeted therapy, and surgery.

Search Trials →Explore Pathway

Understanding Stomach Cancer

Stomach cancer affects ~6,500 people per year in the UK. It often presents late with symptoms like indigestion, weight loss, nausea, and difficulty swallowing. Risk factors include H. pylori infection, smoking, high salt intake, and family history. HER2-positive stomach cancer (~20% of cases) responds to targeted therapy. Survival has improved with better surgery techniques and new systemic treatments.

Treatment Pathway

Operable: perioperative chemotherapy (FLOT regimen) followed by surgery (gastrectomy). HER2-positive metastatic: trastuzumab + chemotherapy (first-line), with trastuzumab deruxtecan (T-DXd) as second-line (DESTINY-Gastric06). HER2-negative metastatic: immunotherapy + chemotherapy - nivolumab + FOLFOX/XELOX (CheckMate-649) or pembrolizumab for MSI-H tumours. Second-line options include ramucirumab + paclitaxel, and trifluridine-tipiracil.

Clinical Trial Opportunities

Active UK stomach cancer trials include: novel immunotherapy combinations, ADCs targeting CLDN18.2 (zolbetuximab), bispecific antibodies, neoadjuvant immunotherapy, and biomarker-driven approaches. The NHS has specialist upper GI cancer centres with multidisciplinary teams.